| Expression pattern: |
UP |
| Associated gene: |
IGF2BP2, PKM2, FTO |
| Associated microRNA: |
- |
| Biological function: |
promotes HCC cell proliferation and glycolysis; promotes tumor growth |
| Molecular mechanism: |
FTO-mediated m6A modification enhances circGDI2 stability/expression; circGDI2 interacts with the m6A reader IGF2BP2 and regulates/stabilizes PKM2 mRNA, promoting glycolysis and proliferation |
| Biological pathway or process: |
glycolysis (promotes); proliferation (promotes); apoptosis (inhibits); m6A modification (other); mRNA stability (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; RNase R Treatment; FISH / smFISH; Clinical Sample Validation; Transfection; CCK8; Luciferase Reporter Assay; MeRIP / MeRIP-seq; Western Blot; In Vivo Animal Model; H&E Staining; IHC (Immunohistochemistry); TUNEL; Bioinformatics Analysis |
| Clinical significance: |
circGDI2 as a potential therapeutic target for HCC |
| Description: |
circGDI2 is up-regulated in hepatocellular carcinoma tissues and cell lines and mainly localizes to the cytoplasm. It promotes HCC proliferation, glycolysis, and tumor growth by interacting with the m6A reader IGF2BP2 to enhance PKM2 expression/stability, while FTO-dependent m6A modification increases circGDI2 stability and expression, reinforcing the circGDI2-IGF2BP2-PKM2 axis. |
| Confidence score: |
0.817 |